SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma terminates transaction agreements with Daiichi Sankyo

27 May 2016 Evaluate

Sun Pharmaceutical Industries has terminated the umbrella pact and transaction agreements with Daiichi Sankyo and its overseas subsidiaries due to divestment of Ranbaxy by the Japanese firm. Daiichi Sankyo, Daiichi Sankyo (Thailand), Sun Pharmaceutical Industries, Ranbaxy (Netherlands) BV and Ranbaxy (Thailand) Company entered into a termination agreement on May 26, 2016 and agreed that the umbrella agreement as well as the executed transaction agreements will be terminated with effect as of the closing date.

There is no material impact of such termination on either standalone or consolidated operations/ financial operations of the company. Additionally, the said termination agreement does not apply to, or have an impact upon, other business relationship that the parties to the said termination agreement may have in force.

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.

Sun Pharma. Inds. Share Price

1904.65 33.10 (1.77%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: